In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
